Patient characteristics before ifosfamide, carboplatin, and etoposide chemotherapy
| Patient characteristics . | No. patients . |
|---|---|
| Age | |
| Median (range) | 27 (12-59) |
| Response to primary therapy | |
| Primary refractory | 22 |
| Relapsed disease | 43 |
| Histology (WHO classification) | |
| Nodular sclerosis | 56 |
| Mixed cellularity | 7 |
| Lymphocyte predominant | 2 |
| Prior radiotherapy | |
| Yes | 39 |
| No | 26 |
| B symptoms pre-ICE | |
| Yes | 16 |
| No | 49 |
| Extranodal sites of disease pre-ICE | |
| Yes | 32 |
| No | 33 |
| Relapsed disease | |
| CR < 1 y | 13 |
| CR > 1 y | 30 |
| Prior chemotherapy | |
| ABVD | 32 |
| MOPP/ABVD | 11 |
| MOPP/ABV | 3 |
| MOPP | 3 |
| Other or multiple | 16 |
| Median no. prior regimens (range, 1-6) | 1 |
| Prognostic model | |
| 0-1 factor | 40 |
| 2 factors | 15 |
| 3 factors | 10 |
| Patient characteristics . | No. patients . |
|---|---|
| Age | |
| Median (range) | 27 (12-59) |
| Response to primary therapy | |
| Primary refractory | 22 |
| Relapsed disease | 43 |
| Histology (WHO classification) | |
| Nodular sclerosis | 56 |
| Mixed cellularity | 7 |
| Lymphocyte predominant | 2 |
| Prior radiotherapy | |
| Yes | 39 |
| No | 26 |
| B symptoms pre-ICE | |
| Yes | 16 |
| No | 49 |
| Extranodal sites of disease pre-ICE | |
| Yes | 32 |
| No | 33 |
| Relapsed disease | |
| CR < 1 y | 13 |
| CR > 1 y | 30 |
| Prior chemotherapy | |
| ABVD | 32 |
| MOPP/ABVD | 11 |
| MOPP/ABV | 3 |
| MOPP | 3 |
| Other or multiple | 16 |
| Median no. prior regimens (range, 1-6) | 1 |
| Prognostic model | |
| 0-1 factor | 40 |
| 2 factors | 15 |
| 3 factors | 10 |
WHO indicates the World Health Organization; ICE, ifosfamide, carboplatin, and etoposide; CR, complete response; ABVD, adriamycin, bleomycin, vinblastine, and dacarbazine; MOPP, mechlorethamine, vincristine, procarbazine, and prednisone.